ArticleAbdominal radiology (New York)2026
Distinguishing enhancing from non-enhancing hyperdense adnexal lesions with spectral reconstructions at photon counting CT.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyperdense adnexal lesions on conventional CT often necessitate follow-up imaging. Photon counting CT (PCCT) allows for the generation of virtual unenhanced (VUE) and iodine map images. The purpose was to investigate the utility of PCCT spectral reconstructions to distinguish enhancing from nonenhancing hyperdense adnexal lesions.
methodsA retrospective Picture Archiving and Communication System (PACS) search identified adult women with adnexal lesions on contrast-enhanced PCCT and with pelvic MRI or ultrasound within 180 days characterizing the lesion, the reference standard. Patients with adnexal lesions > 1 cm and > 20 Hounsfield Units (HU) on 70 keV PCCT images were included. Two radiologists drew region-of-interest measurements independently on adnexal lesions on thin-client software. Attenuation on VUE and 70 keV images, iodine density (ID), and iodine density normalized to aortic enhancement (NID) were recorded from the same region-of-interest. Attenuation change (ΔHU) from VUE to 70 keV was computed. Wilcoxon rank-sum test was used to compare ID, NID, and ΔHU for enhancing versus nonenhancing lesions. Receiver-operating characteristic (ROC) curves were used to determine optimal thresholds for enhancement. Inter-reader agreement was assessed with intraclass correlation coefficients (ICC).
results38 women (median [Interquartile Range (IQR)] age: 44[37,48]) were included. 22 had nonenhancing and 16 had enhancing lesions. ΔHU for enhancing and nonenhancing lesions was 27[24,37]HU and 2[-1,5]HU, respectively (p<.001). ID of enhancing and nonenhancing lesions was 1.15[0.98,1.60] mg/ml and 0.05[-0.08,0.18] mg/ml, respectively (p<.001). NID of enhancing and nonenhancing lesions was 22[14,29]% and 1.0[-1.0,3.0]%, respectively (p<.001). The optimal ΔHU for detecting enhancement at 70 keV was 12.0HU with 100% sensitivity and 95% specificity (Area Under the Curve (AUROC) = 0.99[95% Confidence Interval (CI): 0.97,1.00]). 0.4 mg/mL ID and 8% NID both had 100% sensitivity and 95% specificity (AUROC = 0.99[95%CI: 0.97,1.00]; AUROC = 0.99[95% CI: 0.96,1.00]; respectively). ICC[95% CI] was 0.74[0.56,0.86].
conclusionAttenuation change utilizing VUE images and iodine quantification can differentiate enhancing from nonenhancing hyperdense adnexal lesions at PCCT with excellent diagnostic performance. Accurate assessment of hyperdense adnexal lesion enhancement on PCCT may negate the need for follow-up imaging.
Indexed as
Identifiers
42622831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.